UVRBY yields 3.46% · PFE yields 6.13%● Live data
📍 UVRBY pulled ahead of the other in Year 1
Combined, UVRBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UVRBY + PFE for your $10,000?
Universal Robina Corporation operates as a branded food product company in the Philippines and internationally. It operates through three segments: Branded Consumer Foods, Agro-Industrial Products, and Commodity Food Products. The Branded Consumer Foods segment manufactures and distributes a range of salty snacks, chocolates, candies, biscuits, packed cakes, beverages, instant noodles, pasta, and bakery products, as well as ready-to-drink tea products. This segment also manufactures bi-axially oriented polypropylene films that are used in packaging; and flexible packaging materials for various branded products. The Agro-Industrial Products segment engages in hog and poultry farming; and manufacturing and distributing animal feeds, glucose, and soya products, as well as animal health products. The Commodity Food Products segment is involved in sugar milling and refining, as well as flour milling and pasta manufacturing activities. This segment is also involved in renewable energy business. The company sells its branded food products to supermarkets, wholesalers, convenience stores, trading companies, and distributors, as well as consumer food products through retailers and distributors to approximately 250,000 retail outlets. Its licensed brands include Nissin Cup Noodles, Nissin Yakisoba Instant Noodles and Nissin Pasta Express, Vitasoy, Calbee and B'lue, and others. The company was incorporated in 1954 and is headquartered in Quezon City, the Philippines. Universal Robina Corporation is a subsidiary of JG Summit Holdings, Inc.
Full UVRBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.